The Changes of Plasma Urotensin Ⅱ and Adrenomedullin in Patients with Chronic Heart Failure

游卫华,王评,张凤玲,刘晓剑,李茂清
DOI: https://doi.org/10.3969/j.issn.1007-9688.2009.03.010
2009-01-01
Abstract:Objectives To observe the changes of the concentration of urotensin Ⅱ ( U Ⅱ ) , adrenomedullin ( ADM) in plasma in patients with chronic heart failure ( CHF) and their clinical implications. MethodsThe concentration of UⅡ, ADM in plasma and the left ventricular ejection fraction (LVEF), left ventricular mass index ( LVMI) of 90 patients with CHF ( CHF group) and 60 healthy subjects ( control group) were measured and analyzed. Results The concentration of UⅡ, ADM in plasma were significantly higher in the CHF group than in the control group [(38.22±8.28) ng / L vs. (17.58±3.43) ng / L, P0.01; (3.29±0.92) pmol / L vs. (1.85±0.45) pmol / L, P0.01]; The levels of plasma UⅡ and ADM increased parallel with the severity of heart failure; The concentration of UⅡ in plasma negatively correlated with LVEF, and positively correlated with LVMI and ADM; Compared before and after treatment, there were significant differences in CHF patients with ADM and UⅡ [(29.61±6.88) ng / L vs. (38.31±8.11) ng / L, P0.01; (2.52±0.49) pmol / L vs. (3.43±1.02) pmol / L, P0.01]. Conclusions The concentration of U Ⅱ , ADM in plasma increased with the severity of heart failure. U Ⅱ , ADM fellowship CHF pathology physiological process. The concentration of U Ⅱ in plasma in CHF patients may serve as an index of the severity of CHF and the assessment for treatment effect.
What problem does this paper attempt to address?